How to get a free gallium-68 PSMA-11 PET/CT scan (and yes, there IS a catch)

A research team at the University of California, Los Angeles (UCLA) is seeking participants for a randomized, Phase III, clinical trial of the utility of 68Ga-PSMA-11 PET/CT molecular imaging for planning of salvage radiotherapy after first-line treatment for localized prostate cancer. … READ MORE …

How urologists are thinking about focal therapy for localized prostate cancer

A newly published study in Urologic Oncology has reported data from a survey carried out by researchers at the National Cancer Institute into “the current practice patterns and views among urologists regarding focal therapy for prostate cancer”. … READ MORE …

PCaI joins with Cancer ABCs to advocate for protection of access to cancer and other drugs

For many years now, here in the USA, access to FDA-approved drugs for the treatment of cancer and other severe forms of disorder have been guaranteed under Medicare. … READ MORE …

First-line treatment for prostate cancer and use of antidepressants

According to a recently reported study in the journal European Urology, men who received first-line surgery or radiation therapy for non-metastatic prostate cancer were significantly more likely to have taken an antidepressant 5 years later than comparable men who didn’t get such treatment. … READ MORE …

New data shows that local prostate radiotherapy improves OS in some men with newly diagnosed, metastatic prostate cancer

New data from the ongoing STAMPEDE trial in the UK and Switzerland has now confirmed that ablative radiation of the prostate itself (debulking of the primary tumor) improves overall survival (OS) in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden but not in those with higher burden of disease. … READ MORE …

ASTRO, ASCO, and AUA strongly endorse shortened course of IMRT for primary therapy

It will come as no surprise to our readers that moderately hypofractionated IMRT (first-line radiation delivered in 20 to 26 treatments or fractions instead of the conventional 40-44 fractions) has received strong endorsement from all of the major US organizations of physicians who treat prostate cancer. … READ MORE …

I-131-MIP-1095 to enter randomized, Phase II clinical trial

As we reported last year, a new radiopharmaceutical has entered the pack. … READ MORE …